TARA Insider Trading Activity and SEC Form 4 Filings
TARA insider trading summary
Over the past 12 months, insiders at Protara Therapeutics, Inc. (TARA) reported 3 sales worth $1.0M by 2 insiders and no open-market purchases on SEC Form 4. Net insider selling was $1.0M.
Latest TARA insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jun 29, 2026 | Jesse Shefferman | CEO and President | Sell | $882K (215,687 @ $4.09) |
| Apr 8, 2026 | Jacqueline Zummo | Chief R&D Officer | Sell | $6K (1,134 @ $5.40) |
| Apr 1, 2026 | Jacqueline Zummo | Chief R&D Officer | Sell | $119K (22,598 @ $5.26) |
| May 14, 2025 | Richard S Levy | Insider | Buy | $64K (20,000 @ $3.19) |
| Mar 26, 2025 | Jacqueline Zummo | Chf Scientific Operations Off | Sell | $96K (21,224 @ $4.53) |
| Sep 12, 2024 | Opaleye Management Inc. | 10% Owner | Sell | $11K (6,500 @ $1.71) |
| Sep 12, 2024 | Opaleye Management Inc. | 10% Owner | Sell | $205K (119,801 @ $1.71) |
| Sep 11, 2024 | Opaleye Management Inc. | 10% Owner | Sell | $3K (1,600 @ $1.71) |
| Sep 11, 2024 | Opaleye Management Inc. | 10% Owner | Sell | $53K (31,000 @ $1.71) |
| Sep 10, 2024 | Opaleye Management Inc. | 10% Owner | Sell | $3K (1,500 @ $1.77) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.